COVID-19 and emerging viral infections: The case for interferon lambda

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

DOI

  • Ludmila Prokunina-Olsson, National Institutes of Health
  • ,
  • Noémie Alphonse, King's College London, The Francis Crick Institute
  • ,
  • Ruth E. Dickenson, King's College London
  • ,
  • Joan E. Durbin, Department of Pathology, St. Louis University, Laboratory Medicine and Immunology, Center for Immunity and Inflammation
  • ,
  • Jeffrey S. Glenn, Stanford University
  • ,
  • Rune Hartmann
  • Sergei V. Kotenko, Center for Immunity and Inflammation, Rutgers - The State University of New Jersey, Newark, Center for Cell Signaling
  • ,
  • Helen M. Lazear, University of North Carolina
  • ,
  • Thomas R. O’Brien, National Institutes of Health
  • ,
  • Charlotte Odendall, King's College London
  • ,
  • Olusegun O. Onabajo, National Institutes of Health
  • ,
  • Helen Piontkivska, Kent State University
  • ,
  • Deanna M. Santer, University of Alberta
  • ,
  • Nancy C. Reich, Stony Brook University
  • ,
  • Andreas Wack, The Francis Crick Institute
  • ,
  • Ivan Zanoni, Harvard University

With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.

OriginalsprogEngelsk
Artikelnummere20200653
TidsskriftJournal of Experimental Medicine
Vol/bind217
Nummer5
ISSN0022-1007
DOI
StatusUdgivet - maj 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 191300213